---
title: "Lysergide (DT120) in Generalized anxiety disorder: Budget impact"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Budget impact. 1 evidence topic quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary/budget-impact"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Budget impact

<a id="heading-1.1.3"></a>

## 1.1.3 Budget Impact of Lysergide

<a id="topic-1.1.3-1"></a>

### Summary

The sponsor states that the price of DT120 ODT has not been established and that reimbursement and coding for DT120 have yet to be established. On its third quarter 2026 earnings call, the sponsor stated a commercial pricing corridor of $30,000 to $75,000 per treatment course, based on preliminary payer feedback on the interventional psychiatry market, and related it to current payment for Spravato. Its 2026 corporate presentation estimates a $5B potential gross revenue opportunity from 100K patients treated (24 patients per year across ~4,000 interventional psychiatry clinics) at the midpoint of the Spravato surrogate pricing range, within a target population of 4.2 million U.S. adults with GAD or MDD failed by two or more prescription treatments.

The pivotal trials required 8 hours of monitoring and clearance of an end-of-session checklist; average time to clearance was 5.8 hours in Emerge, 6.4 hours in Voyage, and 6.2 hours in Panorama (Part A). CPT codes 0820T, 0821T, and 0822T describe continuous in-person monitoring during psychedelic medication therapy, each per hour.

Analog evaluations: ICER estimated that 16% of eligible patients could be treated with esketamine at list price without exceeding its $819 million budget impact threshold, assigning a CPT 99214 visit to each dose for the 2-hour observation. For MDMA-assisted psychotherapy, at a $10,000 placeholder price per course, 1.91% of eligible patients could be treated over five years within the $735 million per year threshold.

Burden: in the 2022 US National Health and Wellness Survey (N=75,261), adjusted total direct costs were $11,711 for diagnosed and $18,045 for undiagnosed GAD versus $9,190 without GAD (both p<0.01). In the 2009 and 2010 Medical Expenditure Panel Survey, the annual incremental healthcare expenditure associated with anxiety disorders was $1657.52 per person.

Source: [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [BrainFutures CPT and HCPCS coding guide (2023)](https://www.brainfutures.org/wp-content/uploads/2023/09/A-Guide-to-CPT-and-HCPCS-Codes-for-Psychedelic-Assisted-Therapy_Charts.pdf); [ICER esketamine final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf); [Mustafa et al. (2024)](https://icer.org/wp-content/uploads/2024/06/PTSD_Final-Report_For-Publication_06272024.pdf); [Duong et al. (2024e)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4015/143843); [Shirneshan et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24135257/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
